Dr. Kunz specializes in the treatment of gastrointestinal malignancies with an expertise in the care of patients with neuroendocrine tumors.  She has developed broad investigative programs in the field of neuroendocrine tumors, encompassing clinical trials, population sciences, and translational correlates.  She is the Principal Investigator on numerous Phase I, II and III clinical trials.  She currently serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel, the NCI Neuroendocrine Tumor Taskforce, and the NANETS Executive Committee and Board of Directors as well as the Membership and Diversity Committee.

Dr. Kunz joins Yale from Stanford University School of Medicine where she was Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship. Beyond her record of accomplishment in GI Oncology, Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis.

Read more about Dr. Kunz’s appointment at Yale: https://medicine.yale.edu/news-article/22703/.